LLY241018P740000
- 0.03
- -0.19-86.36%
Eli Lilly and Co Newsroom
FDA 'Three Reflections' removed eli lilly and co (LLY.US) weight loss drug from the shortage list, Hims & Hers Health (HIMS.US) promptly rose by 10%.
After the FDA decided to remove Eli Lilly and Co's tirzepatide from the list of pharmaceutical shortages, a lawsuit related to this delisting caused Hims & Hers Health (HIMS.US) to rise on Monday, closing up about 10%.
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Hims +6% Monday After FDA Said it Might Halt Hims Weight Loss Drug Sales Friday
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Leerink Partners Initiates Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $990
Eli Lilly's (NYSE:LLY) Crohn's Disease Drug Outperforms JNJ's Version
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
Lilly Reports Positive Data for Omvoh Versus Stelara in Crohn's
Amgen's stock price has dropped, analysts warn that the speculation on weight loss drugs has already been digested by the market.
Amgen Inc.'s stocks fell on Monday after an analyst no longer holds a bullish view on this biotechnology giant, citing concerns that investor optimism about a candidate obesity drug has been reflected in the stock price, with more downside risks than upside opportunities. Truist analyst Srikripa Devarakonda downgraded the stock from buy for the past 11 months to hold. However, she raised the target price from $320 to $333, but the new target price is only 1.4% higher than last Friday's closing price. The stock traded down 1.1% in pre-market trading, following a rise last Friday
'Most Widely Hated' Bull Market Reaches 2-Year Milestone: Top 20 S&P 500 Stocks Driving The Rally
Eli Lilly and Company (LLY): Growth Driven by Patents and Pipeline Milestones
Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.
eli lilly and co (LLY.US) shifts investment focus to europe, investing 0.36 billion US dollars in the biotechnology sector in the united kingdom.
The pharmaceutical giant will also study the promotion of anti-obesity drugs in the united kingdom; the Labour government in the united kingdom is trying to attract more foreign investment.
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Eli Lilly to Invest GBP279 Million in UK Life Sciences Sector
Eli Lilly to Invest $364 Million on Obesity-Focused UK Life Sciences Incubator
Express News | Eli Lilly and Co - Submits Marketing Authorization Applications for Mirikizumab Globally
Express News | Eli Lilly and Co - Mirikizumab Safety Profile in Crohn's Disease Consistent With Ulcerative Colitis